Effect of a Nutritional Supplement of Probiotics and/or Prebiotics vs Placebo on Serum Concentrations of Uremic Toxins and Inflammatory Cytokines in Automated Peritoneal Dialysis Patients.
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 112
- 试验地点
- 2
- 主要终点
- Change of uremic toxins from basal to 1 and 3 months
研究概览
简要总结
End-stage renal disease (ESRD) is a world public health problem, with high morbidity and mortality. Cardiovascular disease is the main cause of mortality in ESRD; uremic toxin retention and inflammation are considered non-traditional risk factors, as they have an active role in atherosclerosis and vascular calcification pathogenesis in dialysis patients.
Uremic toxins may be generated by internal protein metabolism, however, some toxins that can't be efficiently eliminated by dialysis such as indoxyl sulphate and p-cresyl sulphate (protein bound toxins), are generated by the microbial metabolism in the large intestine by proteolytic bacteria, and may diffuse easily through the intestinal lumen, as a leaky gut characterizes kidney disease.
The gut has been recognized as a potential source of inflammation in ESRD patients; accumulation of nitrogen compounds, presence of gastrointestinal symptoms, dietary changes and multiple drugs and supplements use, stimulates microbiota alterations as bacterial overgrowth and translocation. These phenomena, may active the immune system, promoting local and systemic inflammation, which in turn has negative effects increasing endothelial dysfunction, muscle catabolism, insulin and erythropoietin resistance, and decreases appetite.
Some methods have been proposed to decrease inflammation and uremic toxin accumulation, as more efficient dialysis and anti-inflammatory drugs; however, some of them have limited efficacy and high cost. Nutritional treatments focused on modifying intestinal environment, as pre- and probiotics have promising effects by altering production and absorption of uremic toxins and decreasing inflammation; nevertheless, there is scarce information regarding its use and their role in ESRD, particularly in peritoneal dialysis, which is a widely used therapy in México. Furthermore, there is no clinical study comparing the effectiveness of prebiotics, probiotics, and symbiotics on serum concentrations of uremic toxins and inflammation in ESRD patients. It is possible that the administration of a nutritional supplement of probiotics and/or prebiotics decreases the serum concentrations of uremic toxins and inflammation markers in ESRD patients on automated peritoneal dialysis compared to placebo.
详细描述
Objective:
The aim of the present study is to evaluate and to compare the effect of a nutritional supplement of probiotics and/or prebiotics on serum concentrations of uremic toxins and inflammatory markers compared to placebo, in automated peritoneal dialysis patients.
Sample size:
For the sample size calculation a mean differences formula was used, with a 95% confidence level, a 80% sample power and accuracy of 0.05. As a reference, the study of Salmean YA, 2015 was considered; in this study, the administration of pea fiber + inulin during 12 weeks in chronic kidney disease patients, significantly decreased (p<0.05) serum concentrations of p-cresol (5.82 ± 1.72 mg/L) in comparison to placebo (7.25 ± 1.74 mg/L). After substituting formula values and adding 20% of possible losses during follow-up, the sample size is: 28 patients.
Additionally, sample size calculation was made considering other outcomes. In the study of Xie LN, 2015, the administration of high-fermentable soluble fiber in ESRD patients on hemodialysis during 6 weeks, significantly decreased (p<0.05) inflammation markers: C-reactive protein (CRP), tumour necrosis factor alpha (TNFa) and interleukin 6 (IL-6) (4.8 ± 4.5 pg/mL, 10.1 ± 1.4 pg/mL, 31.8 ± 5.3 mg/L, respectively) compared to control group (9.5 ± 5.6 pg/mL, 13.1 ± 2.4 pg/mL, 51.5 ± 14.6 mg/L). After substituting the formula, sample size was 19, 7, and 5 for CRP, TNFa and IL-6, respectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Patient Blinding: Patients in automated peritoneal dialysis will be blinded to the intervention they will receive. Evaluator Blinding: The principal investigator and the Doctorate program student will be blinded to the intervention that patients will receive (probiotic, prebiotic, symbiotic or placebo).
Care providers will be blinded to the intervention groups.
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •>3 months on automated peritoneal dialysis treatment
- •Signed informed consent
排除标准
- •ESRD of inflammatory cause (lupus, vasculitis, collagenopathies)
- •Intake of probiotics, prebiotics or fiber in the last 3 months
- •Use of anti-inflammatory drugs or nutritional supplements (immunossuppresants, pentoxifylline, NSAIDs, omega-3)
- •Treated with antibiotics or sevelamer
- •Treated with research drugs or participants in any clinical trial
- •Peritonitis or active infection 2 weeks prior the study
- •Any medical condition affecting intestinal absorption (inflammatory bowel disease, short bowel syndrome, bariatric surgery) or severe dysmotility
- •Severe malnutrition
- •Previous kidney transplantation
- •Serious diseases altering the fina outcomes of the study: decompensated heart failure, chronic liver disease, cancer, AIDS.
研究组 & 干预措施
Probiotic
Subjects receiving probiotic supplementation: 2x108 CFU probiotic bacteria + prebiotic placebo per day during 3 months
干预措施: Probiotic (Dietary Supplement)
Prebiotic
Subjects receiving prebiotic supplementation: 20 g of prebiotic fiber + probiotic placebo per day during 3 months
干预措施: Prebiotic (Dietary Supplement)
Symbiotic
Subjects receiving probiotic and prebiotic supplementation: 2x108 CFU probiotic bacteria + 20 g of prebiotic fiber per day during 3 months
干预措施: Symbiotic (Dietary Supplement)
Placebo
Subjects receiving placebo of probiotic and prebiotic per day during 3 months
干预措施: Placebo (Dietary Supplement)
结局指标
主要结局
Change of uremic toxins from basal to 1 and 3 months
时间窗: Baseline, 1 month and 3 months
Measurement of serum concentrations of the uremic toxins p-cresyl sulphate (mg/dL) and indoxyl sulphate (mg/dL) by means of liquid chromatography.
次要结局
- Change in gut microbiota composition from basal to 1 and 3 months(Baseline, 1 month and 3 months)
- Change in gastrointestinal symptoms from basal to 1 and 3 months(Baseline, 1 month and 3 months)
- Change of inflammatory cytokines from basal to 1 and 3 months(Baseline, 1 month and 3 months)
研究者
Alfonso Martín Cueto Manzano
Head of the Biomedical Research Unit 02
Unidad de Investigacion Medica en Enfermedades Renales
